An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimers disease
Britney N. Lizama, H.A. North, K. Pandey, C. Williams, Duc M. Duong, E. Cho, V. Di Caro, L. Ping, Kaj Blennow, Henrik Zetterberg, James J. Lah, Allan I. Levey, Michael Grundman, Anthony O. Caggiano, Nicholas T. Seyfried, Madison Hamby
This paper reports exploratory CSF proteomics data from a Phase 2 trial of CT1812 in Alzheimer's disease, identifying pharmacodynamic biomarkers and mechanistic insights.
Neurobiology of Disease · Jun 22, 2024Peer-reviewedNeuroscience